Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001140361-13-044117
Filing Date
2013-11-25
Accepted
2013-11-25 18:36:34
Documents
1
Period of Report
2013-11-13

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 6837
  Complete submission text file 0001140361-13-044117.txt   9131
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 152 WEST 57TH STREET 54TH FLOOR NEW YORK NY 10019
Business Address 152 WEST 57TH STREET 54TH FLOOR NEW YORK NY 10019 212-581-0500
Platinum Partners Value Arbitrage Fund, LP (Reporting) CIK: 0001299265 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 131242121

Mailing Address 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Business Address 152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019 (212) 582-2222
Platinum-Montaur Life Sciences, LLC (Reporting) CIK: 0001404598 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-35076 | Film No.: 131242122